Collaborative Pharmacy Practice for Chronic Health Conditions
Summary
SB 294 amends Florida’s collaborative pharmacy practice law for chronic health conditions. Under current law, pharmacists working under a collaborative practice agreement may help manage certain chronic conditions such as arthritis, asthma, COPD, type 2 diabetes, HIV/AIDS, obesity, and other conditions adopted by rule. This bill narrows that definition by expressly excluding three heart-related conditions: heart failure, coronary heart disease, and cardiac rhythm disorders.
The practical effect is to limit the scope of pharmacist-led collaborative care for those excluded cardiac conditions while leaving the rest of the chronic-condition list intact. The bill does not create a new program or funding source; instead, it changes who may be included in collaborative pharmacy practice agreements under section 465.1865, Florida Statutes, beginning July 1, 2025.
Impact
The bill amends section 465.1865, Florida Statutes, by revising the statutory definition of "chronic health condition" for purposes of collaborative pharmacy practice. As a result, pharmacists and other health professionals using collaborative practice agreements will no longer be able to rely on this statute to include patients with heart failure, coronary heart disease, or cardiac rhythm disorders within the covered chronic-condition category. The change affects pharmacy practice, physician/pharmacist collaboration, and patient management for those specific cardiac diagnoses, while preserving existing authority for the other listed chronic conditions and any additional conditions adopted by rule.
Sentiment
The available voting history shows strong, unanimous support at every stage of the Senate process, with no recorded dissent in committee or on the floor. The bill passed the Senate Health Policy committee 9-0, the Appropriations Committee on Health and Human Services 10-0, Senate Rules 25-0, and third reading 38-0. With no committee transcripts provided, the overall sentiment appears broadly favorable and noncontroversial among senators.
Contention
No explicit controversy is reflected in the available materials, and the recorded votes were unanimous. The only notable policy issue is the bill’s decision to exclude heart failure, coronary heart disease, and cardiac rhythm disorders from the chronic health condition definition, which may limit pharmacist involvement in managing some cardiovascular patients. Any concern would likely come from stakeholders who favor broader collaborative practice authority for chronic disease management, while supporters appear to view the change as a targeted clarification or restriction within the pharmacy practice framework.